The US Food and Drugs Administration (FDA) is expected to approve the JenaValve Trilogy System, a transcatheter aortic valve replacement (TAVR) device designed for aortic regurgitation (AR), by late ...
IRVINE, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results